BlackRock
BEAM icon

BlackRock’s Beam Therapeutics BEAM Stock Holding History

BlackRock’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309M Buy
8,997,542
+509,973
+6% +$15.4M ﹤0.01% 1534
2026
Q1 		$202M Buy
8,487,569
+37,387
+0.4% +$1.04M ﹤0.01% 1664
2025
Q4 		$234M Buy
8,450,182
+301,977
+4% +$7.7M ﹤0.01% 1577
2025
Q3 		$198M Buy
8,148,205
+145,516
+2% +$2.89M ﹤0.01% 1665
2025
Q2 		$136M Sell
8,002,689
-99,967
-1% -$1.74M ﹤0.01% 1851
2025
Q1 		$158M Buy
8,102,656
+430,717
+6% +$11.3M ﹤0.01% 1730
2024
Q4 		$190M Sell
7,671,939
-76,325
-1% -$1.95M ﹤0.01% 1699
2024
Q3 		$190M Buy
7,748,264
+113,885
+1% +$2.94M ﹤0.01% 1694
2024
Q2 		$179M Buy
7,634,379
+928,753
+14% +$22.8M ﹤0.01% 1682
2024
Q1 		$222M Buy
6,705,626
+43,583
+0.7% +$1.36M 0.01% 1579
2023
Q4 		$181M Buy
6,662,043
+139,388
+2% +$3.46M ﹤0.01% 1709
2023
Q3 		$157M Buy
6,522,655
+171,879
+3% +$4.61M ﹤0.01% 1704
2023
Q2 		$203M Buy
6,350,776
+1,060,104
+20% +$34.4M 0.01% 1566
2023
Q1 		$162M Buy
5,290,672
+52,031
+1% +$2.05M ﹤0.01% 1698
2022
Q4 		$205M Sell
5,238,641
-127,258
-2% -$5.7M 0.01% 1513
2022
Q3 		$256M Buy
5,365,899
+210,215
+4% +$12M 0.01% 1300
2022
Q2 		$200M Buy
5,155,684
+1,117,493
+28% +$44.4M 0.01% 1533
2022
Q1 		$231M Sell
4,038,191
-24,603
-0.6% -$1.61M 0.01% 1567
2021
Q4 		$324M Buy
4,062,794
+542,819
+15% +$46.5M 0.01% 1370
2021
Q3 		$306M Buy
3,519,975
+345,588
+11% +$34.7M 0.01% 1388
2021
Q2 		$409M Buy
3,174,387
+82,576
+3% +$6.58M 0.01% 1193
2021
Q1 		$247M Sell
3,091,811
-67,699
-2% -$6.44M 0.01% 1584
2020
Q4 		$258M Buy
3,159,510
+931,108
+42% +$45.8M 0.01% 1422
2020
Q3 		$54.9M Buy
2,228,402
+903,808
+68% +$22.4M ﹤0.01% 2237
2020
Q2 		$37.1M Buy
1,324,594
+70,589
+6% +$1.52M ﹤0.01% 2424
2020
Q1 		$22.6M Buy
+1,254,005
New +$27.3M ﹤0.01% 2550

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock's BEAM Position: Q2 2026 in Review

BlackRock increased its Beam Therapeutics (BEAM) stake by 6% in Q2 2026, buying an estimated $15.4M and bringing the position to 8,997,542 shares worth $309M. The position accounts for ﹤0.01% of the portfolio, ranked #1534.

BlackRock first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $409M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • BlackRock held 8,997,542 shares of Beam Therapeutics worth $309M as of Q2 2026.
  • BlackRock bought 509,973 Beam Therapeutics shares in Q2 2026, an estimated $15.4M.
  • Beam Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1534 holding.
  • BlackRock first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • BlackRock's Beam Therapeutics position peaked at $409M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.